» Articles » PMID: 23893312

The Motor Neuron Response to SMN1 Deficiency in Spinal Muscular Atrophy

Overview
Journal Muscle Nerve
Date 2013 Jul 30
PMID 23893312
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The purpose of this study was to measure and analyze motor unit number estimation (MUNE) values longitudinally in spinal muscular atrophy (SMA).

Methods: Sixty-two children with SMA types 2 and 3 were observed prospectively for up to 42 months. Longitudinal electrophysiological data were collected, including compound motor action potential (CMAP), single motor unit action potential (SMUP), and MUNE.

Results: Significant motor neuron loss and compensatory collateral reinnervation were noted at baseline. Over time, there was a significant mean increase in MUNE (4.92 units/year, P = 0.009), a mean decrease in SMUP amplitude (-6.32 μV/year, P = 0.10), and stable CMAP amplitude.

Conclusions: The unexpected longitudinal results differ from findings in amyotrophic lateral sclerosis studies, perhaps indicating that compensatory processes in SMA involve new motor unit development. A better understanding of the mechanisms of motor unit decline and compensation in SMA is important for assessing novel therapeutic strategies and for providing key insights into disease pathophysiology.

Citing Articles

Intersession Intra-Rater and Inter-Rater Reliability of Myotonometer for Upper and Lower Extremity Muscles in Children with Spinal Muscular Atrophy.

Kutluturk Yikilmaz S, Saldiran T, Ozturk O, Oktem S Diagnostics (Basel). 2024; 14(20).

PMID: 39451623 PMC: 11506227. DOI: 10.3390/diagnostics14202300.


Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study.

Wang N, Hu Y, Jiao K, Cheng N, Sun J, Tang J J Neurol. 2024; 271(9):6004-6014.

PMID: 39030456 DOI: 10.1007/s00415-024-12567-y.


Differential impact on motor unit characteristics across severities of adult spinal muscular atrophy.

Kelly K, Mizell J, Bigdeli L, Paul S, Tellez M, Bartlett A Ann Clin Transl Neurol. 2023; 10(12):2208-2222.

PMID: 37735861 PMC: 10723249. DOI: 10.1002/acn3.51906.


Identifying Biomarkers of Spinal Muscular Atrophy for Further Development.

Glascock J, Darras B, Crawford T, Sumner C, Kolb S, DiDonato C J Neuromuscul Dis. 2023; 10(5):937-954.

PMID: 37458045 PMC: 10578234. DOI: 10.3233/JND-230054.


Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach.

Trucco F, Salmin F, Lizio A, Coratti G, Albamonte E, Frisoni M Dysphagia. 2023; 38(6):1568-1580.

PMID: 37289231 PMC: 10611831. DOI: 10.1007/s00455-023-10584-z.


References
1.
Kaufmann P, McDermott M, Darras B, Finkel R, Sproule D, Kang P . Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012; 79(18):1889-97. PMC: 3525313. DOI: 10.1212/WNL.0b013e318271f7e4. View

2.
Glanzman A, OHagen J, McDermott M, Martens W, Flickinger J, Riley S . Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol. 2011; 26(12):1499-507. DOI: 10.1177/0883073811420294. View

3.
Main M, Kairon H, Mercuri E, Muntoni F . The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003; 7(4):155-9. DOI: 10.1016/s1090-3798(03)00060-6. View

4.
Chen T, Chang J, Yang Y, Mai H, Liang W, Wu Y . Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology. 2010; 75(24):2190-7. DOI: 10.1212/WNL.0b013e3182020332. View

5.
Darras B, Kang P . Clinical trials in spinal muscular atrophy. Curr Opin Pediatr. 2007; 19(6):675-9. DOI: 10.1097/MOP.0b013e3282f1884c. View